Menopause HRT: evidence, options and costs

Here's the short version. Hormone therapy is an option for bothersome menopause symptoms after an individual risk assessment. Systemic treatment and local vaginal treatment differ in exposure, goals and precautions. The 2025–26 FDA warning changes do not erase cardiovascular, breast or endometrial risks. Compare the exact product and care plan rather than treating all hormone formulations as one treatment.

What HRT is

Systemic estrogen is generally paired with a progestogen for endometrial protection when a uterus is present. Local vaginal products have distinct exposure and treatment goals; ask about the actual preparation rather than applying one systemic rule to every vaginal product. Around menopause your body makes less estrogen and progesterone. That drop drives hot flashes, night sweats, sleep trouble, vaginal dryness and painful sex, and bone loss over time ^[5].

FDA sorts HRT into four types ^[5]:

• Combination therapy. Estrogen plus a progestogen, for women with a uterus. Usually a pill or patch.
• Systemic estrogen alone. Pills, patches, spray, gel or a systemic vaginal ring. Usually after a hysterectomy.
• Progestogen alone. Pills added to estrogen-alone therapy to protect the uterus.
• Vaginal estrogen. Cream, tablet, insert or ring for vaginal symptoms.

If night sweats are wrecking your sleep, the sleep side of this is on our sleep and recovery shortlist. For the whole hormones picture, start with the hormones shortlist.

Why a progestogen: the uterus rule

Unopposed systemic estrogen raises endometrial-cancer risk in a woman with a uterus. Adding an appropriate progestogen reduces endometrial hyperplasia risk, which can precede cancer; it does not guarantee absence of cancer. That's why the one boxed warning FDA is keeping reads "endometrial cancer with unopposed estrogen in women with a uterus" on systemic estrogen-alone products like Divigel gel ^[9].

Prometrium, the FDA-approved micronized progesterone capsule, is labeled to prevent endometrial hyperplasia in postmenopausal women with a uterus who take conjugated estrogens ^[10]. Bijuva combines estradiol and progesterone in one capsule for women with a uterus ^[11]. Without a uterus, estrogen alone is generally used, but exceptions such as an endometriosis history can matter. Your clinician determines the plan and the actual product label applies.

What changed at FDA in 2025 and 2026

FDA is removing boxed-warning references to heart disease, breast cancer and probable dementia, but keeping the endometrial-cancer warning for systemic estrogen alone. On November 10, 2025 it asked every maker of menopause hormone therapy to change its label ^[2]. The request, in plain terms:

• Take cardiovascular disease, breast cancer and probable dementia out of the boxed warning on every HRT product.
• Keep the endometrial-cancer box on systemic estrogen-alone products; drop it elsewhere.
• Drop the "lowest dose for the shortest time" line and the probable-dementia warning.
• On systemic products, add that starting HRT can be considered for moderate to severe hot flashes in women under 60 or within 10 years of menopause.
• Keep the heart and breast cancer risks in the Warnings and Precautions section.

That last point matters. The risks didn't vanish; they moved out of the box. FDA says it has not asked companies to remove cardiovascular disease and breast cancer from Warnings and Precautions ^[5].

What the big trials found

The Women's Health Initiative (WHI) trials found risks that depended on age and regimen, and no statistically significant difference in long-term overall mortality. They're the reason the old warnings existed, so the numbers are worth knowing.

In the estrogen-plus-progestin trial, 16,608 women aged 50 to 79 with a uterus took conjugated estrogens plus medroxyprogesterone or placebo. After about 5.2 years, the hormone group had more heart disease (hazard ratio 1.29), breast cancer (1.26), stroke (1.41) and blood clots in the lung (2.13). It also had fewer colorectal cancers (0.63) and hip fractures (0.66) ^[13].

In the estrogen-alone trial, 10,739 women who'd had a hysterectomy took conjugated estrogens or placebo. Stroke rose (1.39), hip fractures fell (0.61), and heart disease didn't change (0.91) ^[14].

Age changed the picture. Over 13 years of follow-up, the combined regimen's breast cancer hazard ratio was 1.28, while estrogen alone came in at 0.79. Absolute risks were lowest in women aged 50 to 59 ^[15]. And after 18 years, death from any cause was 27.1% on hormones vs 27.6% on placebo, a hazard ratio of 0.99 (95% CI 0.94–1.03) ^[16].

"Bioidentical": FDA-approved vs compounded

Estradiol and micronized progesterone in FDA-approved products are chemically identical to the hormones your body makes. So "bioidentical" doesn't mean compounded. FDA puts it plainly: it has approved drugs with hormones identical to the ones women make in their reproductive years ^[6].

Compounded bioidentical hormones are different. A pharmacy mixes them to a prescription, often as a cream or troche, and FDA doesn't review them before they're dispensed. FDA says it has no evidence that compounded "bioidentical hormones" are safe and effective, or safer or more effective than approved hormone therapy ^[6]. The 2020 National Academies report found no rigorous evidence of safety and effectiveness. Its findings support asking why an approved product cannot meet the individual clinical need, rather than assuming a compounded formulation is safer ^[7].

Estriol is the clearest case. The cited FDA resource identifies no FDA-approved estriol drug and describes marketed estriol drugs as compounded ^[6]. You'll see it in body creams and face creams from several online programs. An estriol-containing cream should not be treated as an approved estradiol medicine; confirm its exact ingredients, purpose and dispensing route.

Forms: pill, patch, gel, cream, vaginal

FDA-approved and compounded products can share a route while differing in formulation, evidence and approval status. Confirm the exact product rather than inferring approval from the word pill, patch or cream.

Local vaginal estrogen is used for vaginal-atrophy symptoms. Some vaginal rings deliver systemic treatment, so route alone does not identify exposure or indication. Estring is labeled for moderate to severe vaginal and vulvar atrophy, and its updated label has no boxed warning ^[12]. FDA's request also asked makers of local vaginal products to condense their safety sections ^[2]. Use the specific current label; lower systemic exposure does not mean every systemic risk is absent.

Not a fit for hormones? FDA has also approved three non-hormone treatments for women who can't or don't want to take them ^[5]. Ask your clinician which one fits.

Compare the complete HRT cost

A prescription price and an ongoing care program cover different services. Ask whether visits are billed to insurance or paid directly, whether the medication comes from your pharmacy or a network partner, and whether a recurring membership is required. A headline for one hormone may exclude the other component, monitoring or clinical follow-up.

The AgelessRx review describes one program’s service and membership limitations. Its terms are not universal to menopause care. Use the billing calculator to compare calendar-month and fixed-day charges, and the provider checklist to organize the exact plan.

Insurance and self-pay cover different parts of care

A clinic’s insurance participation does not establish coverage for every medication or service. An HSA/FSA payment option is not the same as insurance reimbursement. Compare the clinical and pharmacy charges separately, including any deductible, copay or authorization requirement. If comparing Midi Health and Winona, confirm the selected program’s current terms before enrollment.

How to get HRT prescribed online

You fill out a health history, a clinician reviews it, and if HRT fits, a pharmacy ships it or you pick it up. The details differ by program:

• Assessment. Discuss symptoms, bleeding, medical history, medications and whether a uterus is present.
• Consultation. Confirm whether the clinician requires video, another encounter or in-person evaluation for your situation.
• Product selection. Identify systemic or local treatment, its exact ingredients, label and dispensing pharmacy.
• Follow-up. Agree on reassessment, monitoring, side-effect reporting and the actual renewal schedule.

Expect questions about your periods, bleeding, blood clots, breast cancer history and whether you still have a uterus. Answer them fully; they decide what's safe for you. Not sure which program fits how you want to be seen? Take the 30-second match.

Who should not take HRT

The labels list clear no-go conditions. Bijuva's label, for example, rules it out for women with ^[11]:

• Abnormal genital bleeding without a known cause
• Breast cancer, now or in the past
• A known or suspected estrogen-dependent cancer
• An active blood clot in a leg or lung, or a history of one
• Active arterial thromboembolic disease, such as stroke or heart attack, or a history of those conditions
• Liver impairment or disease, known thrombophilic disorders, or hypersensitivity to the actual product

Prometrium capsules contain peanut oil and are contraindicated if you're allergic to peanuts ^[10]. Even on updated labels, stroke, blood clots and breast cancer stay in Warnings and Precautions ^[5]. Your prescriber weighs those against your symptoms.

Questions to ask before you start

Five questions sort out most of the confusion before you pay. Ask them in the intake notes or the first message.

1. Is the product you're prescribing FDA-approved, or compounded? If compounded, why is an approved version not a fit for me?
2. Does it contain estriol? If so, what does it add over estradiol alone?
3. I have a uterus. What protects it on this plan?
4. Which label version does this product carry, the updated one or the older boxed warning?
5. What will month two cost, including any membership, visit fee or shipping?

A good program answers all five in plain words. If one dodges the pharmacy question or the month-two price, that's your cue to look at another option on the hormones shortlist.

Where testosterone fits

Testosterone is not an interchangeable substitute for estrogen-based menopause treatment. The cited modern men’s TRT labels do not establish a menopause indication, while some enanthate labels include a separate oncology indication in selected women. That does not approve female sexual-health or general menopause use. Individualized off-label prescribing requires its own evidence and risk assessment ^[1]. More on that in what testosterone therapy is.